GALT

Galectin Therapeutics Inc

NASDAQ: GALT · HEALTHCARE · BIOTECHNOLOGY

$3.44

-2.55% today

Updated 2026-08-14

Market cap

$347.93M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-0.41

Dividend yield

—

52W range

$2 – $7

Volume

0.7M

Market cap

$347.93M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-0.41

Dividend yield

—

52W range

$2 – $7

Volume

0.7M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

6.0

Quality

3.0

Profitability

5.0

Valuation

C+

3/9

Piotroski F-Score

Weak

-34.3

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →222 stocks currently score above 75

Price targets

Analyst target

$11.00

+219.77%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

0 Strong Buy1 Buy0 Hold0 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths

+ Debt/equity -1.04x — low leverage

Risks

- Piotroski 3/9 — weak financial health

- Altman Z -34.27 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-3.87M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-38.78M	$-41.07M	$-47.05M	$-30.84M	$-5.05M
EPS	—	—	—	—	$-0.41
Free cash flow	$-31.06M	$-32.97M	$-41.77M	$-23.88M	$-3.87M
Profit margin	—	—	—	—	—

Recent insider activity

Date	Insider	Type	Shares	Price
2026-07-31	UIHLEIN, RICHARD E	Buy	31,825,235	$3.00
2026-07-31	UIHLEIN, RICHARD E	Buy	2,550,932	$4.05
2026-07-14	JAMIL, KHURRAM	Sale	16,250	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
GALT	$347.93M	19	4.3	3.0	5.0	6.0	—	Avoid
LLY	$1.02T	76	10.0	10.0	4.3	6.0	—	Strong Buy
JNJ	$614.36B	57	4.7	8.5	3.3	6.0	-87.34%	Buy
ABBV	$430.82B	73	6.7	8.5	4.7	5.0	-64.01%	Strong Buy
UNH	$370.11B	62	7.3	5.5	4.0	6.0	-24.76%	Buy
MRK	$316.14B	50	3.3	7.0	2.7	5.0	-60.87%	Hold

Smart narrative

Galectin Therapeutics Inc trades at $3.44. Our Smart Value Score of 19/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of -34.27, it sits in the distress.

Frequently asked questions

What is Galectin Therapeutics Inc's stock price?

Galectin Therapeutics Inc (GALT) trades at $3.44.

Is Galectin Therapeutics Inc overvalued?

Galectin Therapeutics Inc carries a Smart Value Score of 19/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

What is the price target of Galectin Therapeutics Inc (GALT)?

The 12-month analyst consensus target is $11.00, about 219.8% above the current $3.44. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Altman Z-Score?

Galectin Therapeutics Inc's Altman Z-Score is -34.27, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

galectintherapeutics.com

Quick metrics

P/S ratio—

ROE-3,728.00%

Beta0.35

50D MA$3.48

200D MA$3.61

Shares out0.10B

Float0.00B

Short ratio—

Avg volume0.7M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

GALT vs LLY →GALT vs JNJ →GALT vs ABBV →Stock screener →